Clinical evidence from the PEMBRO-RT trial revealed that combining SBRT with anti-PD-1 therapy doubled objective response rates in PD-L1-negative non-small cell lung cancer (NSCLC) compared to ICI monotherapy (ORR: 36% vs. 18%) (7). The gene discussed is CD274; the disease is non-small cell lung carcinoma.